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Context: Although diabetes affects 40-50% of adults with cystic fibrosis, remarkably little is 
known regarding the underlying mechanisms leading to impaired pancreatic β-cell insulin 
secretion. Efforts towards improving the functional β-cell deficit in cystic fibrosis related 
diabetes (CFRD) have been hampered by an incomplete understanding of whether β-cell 
function is intrinsically regulated by CFTR. Definitively excluding meaningful CFTR 
expression in human -cells in situ would contribute significantly to the understanding of 
CFRD pathogenesis.  
Objective: To determine CFTR mRNA and protein expression within β-cells in situ in the 
unmanipulated human pancreas of donors without any known pancreatic pathology.  
Design: In situ hybridisation for CFTR mRNA expression in parallel with insulin 
immunohistochemical staining; and immunofluorescence co-localisation of CFTR with 
insulin and the ductal marker, Keratin-7, were undertaken in pancreatic tissue blocks from 10 
normal adult, non-obese deceased organ donors over a wide age range (23-71 years) with 
quantitative image analysis. 
Results: CFTR mRNA was detectable in 0.45 (0.17-0.83)% (mean(range)) of insulin-positive 
cells. CFTR protein expression was co-localised with Keratin-7. 100% of insulin-positive 
cells were immunonegative for CFTR. 
Conclusions: For the first time, in situ CFTR mRNA expression in the unmanipulated 
pancreas has been shown to be present in only a very small minority (<1%) of normal adult 
β-cells. These data signal a need to move away from studying endocrine-intrinsic 

























Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene. This encodes an important chloride channel, with loss of protein 
function leading to impaired ion and water transport across epithelial membranes, causing the 
production of viscous mucus in multiple organs, including the lungs, intestines and pancreas. 
As life expectancy for individuals affected by CF has increased, the prevalence of cystic 
fibrosis-related diabetes (CFRD) has risen dramatically, such that it now affects 
approximately 50% of adults (1). Although CF is associated with varying degrees of insulin 
resistance, CFRD is primarily caused by reduced β-cell function leading to insufficient 
insulin secretion (2-3).   
 
The mechanisms through which mutations in CFTR lead to impaired insulin secretion in 
humans remain contentious, with recent reports providing conflicting evidence (reviewed in 
Norris et al., 2019) (4). CFTR expression has been reported in cultured rodent β-cell lines and 
primary rodent islets with impaired CFTR function associated with reduced glucose 
stimulated insulin secretion (5-7). Similarly, CFTR expression has been inferred in human 
islet β-cells, with a small CFTR current detected following whole cell patch clamp studies 
(5). This is supported by CFTR inhibitor studies in which GlyH-101 and CFTRinh-172 were 
reported to cause disruptions in human β-cell stimulus-secretion coupling, suggesting that 
CFTR directly regulates insulin secretion through a β-cell intrinsic mechanism (5). 
Conversely, studies in a ferret CF model have indicated that CFTR is absent from β-cells, 
providing evidence that insulin secretory defects and progression to CFRD can be caused by 






















Absence of CFTR protein immunostaining in β-cells has been reported in four young human 
organ donors without CF (aged 1 day to 4 years) (9). Recent high quality studies have 
detected significant CFTR gene expression in <5% of β-cells following human islet isolation, 
dissociation and single cell RNA sequencing (9-11). Nevertheless unresolved contention 
remains regarding whether or not the CFTR gene is expressed in unmanipulated pancreatic β-
cells in situ. To date, definitive resolution has been precluded by the limited availability of 
suitable human tissue (8), problematic antibodies (9,12), the absence of optimal antibody 
controls (5), and reliance on dissociated pancreatic cells (8,10-11) with the potential for 
misinterpretation arising from islet processing leading to phenotypic alterations (13). To 
address this, we have assessed β-cell CFTR mRNA expression in situ in pancreata from 10 
adult deceased organ donors without any known pancreatic pathology using an in situ 
hybridisation (CFTR) and immunohistochemistry (insulin) dual-labelling approach. 
Appropriately controlled CFTR/insulin immunohistochemical staining studies were 
conducted in parallel. Our findings strongly suggest that insulin secretion in humans is not 
directly regulated by β-cell intrinsic CFTR expression. 
 
Materials and Methods 
Donors and sample processing 
Pancreata were procured from deceased organ donors within accredited facilities by the UK 
National Organ Retrieval Service. Absence of diabetes and other history of pancreatic disease 
was confirmed through the NHS Blood and Transplant Organ Donation and Transplantation 
Electronic Offering System. LDIS174 was a donor following circulatory death (DCD) with 
functional warm ischaemic time of 32 minutes. All others donors followed brainstem death 
(DBD). Pancreata were shipped by licensed organ courier, and the pancreatic tissue was 





















in house) and biopsies for LDIS121 – LDIS204 were fixed in 10% neutral buffered formalin 
(Sigma cat# HT5011-1) at room temperature and were processed for paraffin embedding and 
sectioning (4 m). Tissue processing and sectioning was undertaken within the ISO 
accredited Newcastle Cellular Pathology department (ISO15189:2012). 
 
CFTR knockout ferret pancreas tissue collection and tissue processing 
A ferret CFTR exon-10 disruption model (CFTR knockout) was used to confirm the 
specificity of CFTR protein and mRNA expression in the pancreas (14). This CFTR knockout 
(CFTR KO) model develops spontaneous lung (15) and pancreatic disease (16). 
Heterozygotes for the CFTR gene disruption were mated in Marshall Farms (North Rose, 
NY, US) and pregnant jills gave birth at the University of Iowa (Iowa City, IA, US). 
Genotypes of litters were confirmed soon after birth. Whole pancreata from newborn 
CFTR+/+ (non-CF) and CFTR-/- (CF) littermates were harvested immediately after 
euthanasia. The tissues were fixed in 10% neutral buffered formalin for 72 hours at room 
temperature and routinely processed for paraffin sectioning at 4 m. The unbaked sections 
were stored at room temperature until use. 
 
In Situ Hybridisation and Immunohistochemistry (IHC) 
Tissue sections (4 m) from formalin fixed paraffin embedded pancreas samples were 
evaluated for CFTR RNA expression by in situ hybridisation (ISH) (Advanced Cell 
Diagnostics (ACD); Probe: 503569). CFTR ISH alone was performed on five donors 
(LDIS072, LDIS152, LDIS155, LDIS174 and LDIS204) using RNAscope 2.5 VS reagent kit 
(brown; ACD, 322200) on the Ventana Discovery Ultra according to the manufacturer’s 
instructions including Haematoxylin counter-stain. Dual CFTR ISH (Advanced Cell 





















Polyclonal; Dilution 1:100) IHC (Ventana Discovery Red Kit; 07425333001) was performed 
on all ten donors using RNAscope 2.5 VS reagent kit (brown; ACD, 322200) on the Ventana 
Discovery Ultra according to the manufacturer’s instructions. All studies were performed 
within the Newcastle MRC Molecular Pathology Node. 
 
Slide digitalisation and automated quantification  
For automated determination of CFTR mRNA and insulin protein expression in human 
pancreas sections, slides were scanned (x40 magnification) and digitalised using the Leica 
SCN400 slide scanner. Images were accessed through the Slidepath (Leica Biosystems) DIH 
system and evaluated using the software’s ‘Measure Stained Cells’ algorithm. Details on 
development of this automated algorithm can be found at: https://prd-medweb-
cdn.s3.amazonaws.com/documents/dhsr/files/Tissue_IA_2-0_Training_Presentation.pdf. 
Briefly, pixel inclusion of insulin (red) and CFTR RNA (brown) was determined using the 
colour definition function and inputted in to the algorithm. Prior to whole section analysis, 5 
random fields of view (20x) were assessed in each donor to confirm algorithm accuracy. The 
Tissue IA function was used for image analysis of whole pancreas sections, and data was 
exported to Microsoft Excel. The overall percentage of insulin/CFTR co-expressing cells was 
calculated by dividing the total number of insulin/CFTR-positive cells by the total number of 
insulin-positive cells identified in the whole tissue section of each donor. These data are 
summarised in Table 1. All image files are stored and made available on the Newcastle 
University data repository (17-18). 
 
Immunofluorescence 
Tissue sections (4 m) from formalin fixed paraffin embedded samples were evaluated for 





















Sections were deparaffinised and rehydrated followed by heat-mediated antigen retrieval 
(HIER) performed in 10 mM citrate buffer (pH 6) in a pressure cooker. Following blocking 
in 10% goat serum, sections were incubated with mouse anti-CFTR (596) (Cystic Fibrosis 
Foundation, Chapel Hill, NC; CFTR 596 (A4); 1:2000) primary antibody overnight at 4°C. 
Secondary antibody staining was undertaken with the anti-mouse Alexa Fluor 488 Tyramide 
SuperBoost Kit (ThermoFisher, UK; B40912), according to manufacturer’s instructions. 
Sections were then blocked as described and incubated with either guinea pig anti-insulin 
(Dako, Carpinteria CA, USA; A0564;1:200) or rabbit anti-Keratin-7 (KRT7) (Abcam, 
Cambridge, UK; ab181598; 1:1000) overnight at 4 °C. Primary antibody binding was 
detected by Alexa Fluor 647 conjugated anti-guinea pig or anti-rabbit secondary antibodies 
(Life technologies, CA, USA; A-21450; 1:500). Sections were counterstained with DAPI 
(ThermoFisher, UK; 62248) before being mounted with Vectashield Mounting medium 
(Vector Laboratories, CA, USA; H-1000). 
 
Image acquisition and processing  
Confocal images were acquired on a Leica SP8 point scanning confocal microscope with 
white light super continuum lasers at 40x using a 40x/1.3NA HC PL APO CS2 oil immersion 
lens at Nyquist rate (voxel size: X,Y 46 nm, Z 165 nm) applying 2x line average and 
acquiring each channel sequentially. Images were deconvolved using the Huygens Essential 
(Scientific Volume Imaging, SVI) deconvolution express (standard) algorithm. All images 
were acquired and processed at the Newcastle University Bioimaging Unit. 
 
Statistics and image analysis 
Data are reported as mean (range) or mean SEM, calculated in Prism 8.0.1 for Mac (Prisms, 





















Colocalization Coefficients (MCC) as previously described (19). This was undertaken 
following optimized background estimation process from SVI (www.svi.nl) based on the 
Costes method (20), but without the assumption that the ideal background threshold 
combination is on the regression line.    
 
Study approval 
The study was approved by the National Research Ethical Committee for Wales and written 
informed consent was obtained from donor relatives before any study-related work. 
 
Results 
The study group comprised optimally procured non-obese adult deceased organ donors across 
a wide age range (23-71 years) with no history of diabetes or other pancreatic pathology. 
Demographics are summarised in Table 1, confirming blood glucose level below the 
diagnostic threshold for diabetes in all donors. 
 
To determine whether pancreatic β-cells express CFTR, we investigated CFTR mRNA 
localisation within human pancreas sections (n=5 donors). Initially we undertook in situ 
hybridisation (ISH) for CFTR alone, which revealed expression in a heterogeneous 
distribution throughout the exocrine pancreas (Figure 1a, c). Morphological appearances on 
haematoxylin counter-staining were in keeping with previously published CFTR protein 
staining predominantly in small intra-lobular pancreatic ducts with sparing of islets (Figure 
1b,d) (21). Representative images are presented in Figure 1, and whole slide scans are 






















We next employed an ISH (CFTR) and immunohistochemistry (IHC) (insulin) dual-labelling 
approach to assess CFTR mRNA expression in β-cells in human pancreatic tissue sections 
(n=10 donors). Assessment by transmission light microscopy indicated an absence of 
detectable CFTR mRNA expression in the majority of insulin-containing cells, although rare  
co-expressing cells were detected (Figure 2). Whole slide scans are available digitally (18). 
Automated quantification of digitalised pancreatic sections enabled assessment of 48,416 β-
cells, and only 214 of these had detectable CFTR mRNA (Table 2). CFTR mRNA was thus 
detectable in a mean of 0.45% of insulin-positive cells, with range from the donor with 
lowest proportion to the donor with the highest proportion of 0.17-0.83%. 
 
Evaluation of CFTR protein expression and localisation in situ in human pancreas has 
previously been limited by the small number of available human donors (9). Studies have 
also been hampered by a lack of optimal antibody controls (5) and detailed image analysis 
and quantification (5,9). Given concerns regarding CFTR antibody suitability, particularly for 
use in IHC, we initially assessed the specificity of the anti-CFTR (596) monoclonal antibody 
in pancreatic tissue from newborn wild type (WT) and CFTR knock-out (KO) ferrets. This 
antibody is provided by the Cystic Fibrosis Foundation and has previously been validated for 
use in a range of immunodetection techniques (12). Using immunofluorescence staining, we 
confirmed CFTR expression in WT but not CFTR KO animals (Figure 3). Dual labelling for 
CFTR and insulin demonstrated that CFTR was localised to the exocrine pancreas but was 
not expressed in β-cells which were present as developing islet clusters and as single cells 
dispersed within the exocrine pancreas in WT animals (Figure 3). Having confirmed 
specificity of the CFTR (596) antibody, co-staining with the ductal protein, Keratin 7 (KRT7) 
was undertaken in two human donors. CFTR expression was in keeping with previously 





















larger ducts expressing Keratin-7 alone (21). Following image acquisition, deconvolution and 
signal thresholding, the Manders coefficient for CFTR and KRT7 were 34±2% and 48±2% 
for M1 and M2 respectively, confirming significant co-localisation and thus expression of 
CFTR in human pancreatic ductal cells. Representative images are shown in Figure 4a. 
Using this validated antibody and detection method, we then assessed 116 islets across 10 
donors for insulin and CFTR expression and found no evidence of co-localisation of CFTR 
and insulin i.e M1=0 and M2=0, indicating that CFTR protein cannot be detected by IHC in 
normal human β-cells. Representative images from two donors are shown in Figure 4 b, c.  
 
Discussion 
Using sensitive (dual ISH/IHC) and unbiased (software quantification) methodologies, CFTR 
mRNA expression was detectable in <1% of β-cells in situ in 10 adult deceased organ donors 
(aged 23-71 years) without known pancreatic pathology. Following IHC and co-localisation 
analysis using a validated antibody, CFTR protein expression could not be detected in islet β-
cells. We conclude that CFTR is not expressed in most human β-cells and is thus unlikely to 
play a significant intrinsic role in normal human β-cell function. 
 
Our findings are supported by the sensitive and complementary approach of single cell 
sequencing following tissue dissociation which has found CFTR transcripts at low levels in 
only a small population of sorted β-cells with the majority being devoid of such transcripts 
(9-11). Given that alterations in β-cell gene expression may occur following pancreas 
processing and islet isolation (13), it was important to extend these studies by conducting in 
situ mRNA localisation. Our analysis revealed that co-expression of insulin protein and 
CFTR mRNA is rare, occurring in only 0.45% of the β-cell population examined in 10 





















isolated human β-cells, supporting the absence of meaningful β-cell CFTR mRNA expression 
(8).  
 
In support of our ISH interpretations, we failed to detect the presence of CFTR protein in 
insulin-positive cells following the detailed examination of islets from all 10 donors. These 
observations are in contrast to previous studies reporting CFTR localisation in single human 
β-cells following immunofluorescent staining with the MATG-1061 CFTR antibody (5). 
However, given the recently reported lack of specificity of certain CFTR antibodies (9,12), 
and the omission of a cell control known not to express CFTR, false positivity using MATG-
1061 cannot be excluded. Also, subsequent immunohistochemical staining of human 
pancreas sections using this antibody failed to demonstrate the expected presence of CFTR in 
ductal cells (22).  
 
Here, we assessed CFTR protein localisation using the Cystic Fibrosis Foundation 596 
monoclonal antibody, which has previously been reported as suitable for detection of wild 
type CFTR by immunofluorescence (12). The specificity of this antibody was confirmed by 
the presence of positive CFTR staining in pancreatic tissue samples from wild type ferrets 
and its absence from CFTR knockout animals. As previously reported, insulin-positive cells 
were distributed throughout the pancreatic parenchyma as well as in developing islet clusters 
in the newborn ferret (23). No insulin+ / CFTR+ cells were seen. Co-localisation of CFTR 
with the ductal cell marker, Keratin7, was confirmed in human pancreas. We conclude that 
CFTR protein is not expressed in human β-cells, consistent with the Human Protein Atlas 
(24). While paediatric samples were not included in the current study, absence of detectable 






















These observations lead us to propose that human β-cell dysfunction and progression to 
CFRD is likely to be mediated by factors extrinsic to the pancreatic β-cell. Whilst contrasting 
reports have proposed a direct, intrinsic functional role for CFTR in human insulin secretion 
(5) these conclusions were based predominately on in vitro assessments of human islets 
following treatment with the CFTR inhibitors, CFTR (inh)-172 and GlyH-101. However, 
both these compounds have been reported to inhibit activity of other chloride channels (25) at 
the concentrations used by Edlund et al (5), highlighting the potential limitations in using 
CFTR inhibitors to determine an intrinsic role for CFTR in insulin secretion. This is 
supported by reports that CFTR(inh)-172 (20 M) negatively affects glucose-stimulated 
insulin secretion in islets from CFTR KO in addition to WT ferrets (8), suggesting inhibition 
through a non-CFTR mediated pathway.  
 
Although CFTR protein expression was not detectable in β-cells by IHC, in keeping with 
absence of significant translation even in cells with detectable CFTR mRNA, we cannot 
exclude the technical limitation that the method is not sufficiently sensitive to detect very low 
level CFTR protein expression. Thus, whilst our data suggest that CFTR is not expressed in a 
sufficient number of β-cells at sufficient levels to play an important role in controlling β-cell 
function through stimulus-secretion coupling or other intrinsic mechanisms, it remains 
possible that such a minority population may have functional consequences if, for example, 
they were highly electrically active, such as the hub β-cells that have recently been described 
(26). Alternatively, rare insulin-positive cells expressing CFTR mRNA may represent ductal 
derived neo-endocrine cells in which CFTR protein has been downregulated despite mRNA 
expression persisting. Such extrainsular cells with endocrine differentiation potential have 
been described, however, the presence of CFTR in such cells has not been reported (27). 





















of ‘neo-endocrine’ cells, more definitive phenotyping in situ in unmanipulated pancreas is 
merited.  
 
Clinical studies in CF patients treated with the CFTR potentiator, Ivacaftor, have 
demonstrated improved insulin secretion (28). Our data suggest that this is mediated 
indirectly through improvements in CF pathophysiology in the exocrine pancreas and other 
tissues. In support of this, a direct effect of Ivacaftor on β-cell secretory function was 
disputed in a recent human islet study (9). 
 
Our data exclude CFTR expression in the majority of human β-cells within the intact 
minimally-manipulated pancreas. We propose that further translational research efforts 
should focus on understanding the role of exocrine-endocrine interactions in CFRD 
pathogenesis, and particularly the role of inflammatory mediators, with the goal of diabetes 
remission / prevention through a combinatorial approach limiting pancreatic destruction and 
reversing dysfunction in remaining β-cells. It is hoped that deeper understanding of the 
mechanisms through which extrinsic metabolic stress and proinflammatory factors can 
indirectly impair beta-cell function will facilitate progress towards new therapeutic 
approaches for more prevalent type 2 and type 1 diabetes. 
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Figure legends  
Figure 1. CFTR mRNA localisation in human pancreas (a-d) CFTR mRNA (brown) was 
detected by ISH in pancreas sections of donors without diabetes (n=5). Duct-like structures 
(dotted black lines) and islet-like structures (red arrows) were identified morphologically. 
Boxes (a and c) indicate regions imaged at higher magnification (b and d). Scale bars 
represent 100 m (a and c) and 30 m (b and d). 
 
Figure 2. CFTR mRNA is absent from most human β-cells (a-f) CFTR mRNA (brown) 
and insulin protein (red) were detected using a combination of ISH and IHC in pancreas 
sections from donors without diabetes (n=10). Arrows (e-f) indicate rare insulin-positive cells 
co-expressing CFTR mRNA. Scale bars represent 30 m.   
 
Figure 3. CFTR expression in newborn WT and CFTR KO ferrets Immunofluorescence 
staining for CFTR and insulin protein in pancreas sections from newborn WT (a-c) (n=2) and 
CFTR KO (d-f) ferrets (n=2). Boxes (a and d) indicate the regions imaged at higher 
magnification (b-c and e-f). Scale bars represent 50 m (a and d) and 25 m (b and e). 
 
Figure 4. CFTR protein is undetectable in human β-cells (a-c) Immunofluorescence 
staining for CFTR with Keratin-7 (KRT7) (A) (n=2 donors: LDIS101 and LDIS155.) and 
insulin protein (b-c) (n=10 donors) in pancreas sections from donors without diabetes. 
Cytofluorograms illustrate presence and absence of CFTR colocalization with KRT7 (a) and 
insulin (b-c) respectively. Areas highlighted by white dotted lines indicate islets. Scale bars 




























































           
LDIS072 24 F 25.95 DBD 27 9.4 







DBD 72 n/a 
LDIS121 58 F 21.72 DBD 22.7 6.5 
LDIS124 57 F 23.83 DBD 22.2 7.6 
LDIS152 49 M 25.39 DBD 8.5 6.5 
LDIS155 48 F 22.91 DBD 13.1 6.4 
LDIS156 23 M 21.13 DBD 31.2 7.4 
LDIS174 71 M 26.73 DCD 11.4 7.4 
LDIS204 56 F 26.9 DBD 13.6 9.0 































































       





























































































SEM 8,773 243.9 891.4 27.7 5.4 0.08 
Table 2. Number of cells expressing CFTR (ISH) and insulin (IHC) in a 
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